FDA clears Novo Nordisk's diabetes drug to reduce cardiovascular risk

Evrard Martin
Août 26, 2017

That trial showed that liraglutide cut the risk of CV death by 22% and reduced major CV events by 13% versus placebo, as well as lowering the risk of death from any cause by 15%.

The diabetes drug liraglutide (Victoza) secured an indication from the FDA to reduce the risk of major adverse cardiovascular events in adults with Type 2 diabetes and established cardiovascular disease, Novo Nordisk announced August 25.

The study, which included 9340 participants, investigated the long-term effects of the drug compared to a placebo, both in addition to standard of care, in individuals with type 2 diabetes at a high risk of cardiovascular events. Follow-up time ranged from 42 months to five years.

"Today's news is significant for millions of Americans living with type 2 diabetes because, even when controlled, diabetes puts patients at a greater risk for cardiovascular events", Steve Marso, MD, medical director of cardiovascular services at HCA Midwest Health Heart and Vascular Institute, said in the release.

In December, the FDA had approved Eli Lilly and Co and Boehringer Ingelheim Pharmaceuticals Inc's drug, Jardiance, to reduce the risk of cardiovascular death in patients with type 2 diabetes. "More treatment options like Victoza that address critical aspects of diabetes care beyond glucose lowering are effectual to confront this pervasive issue".

Victoza approved in the United States as the only type 2 diabetes treatment indicated to reduce the risk of major adverse cardiovascular events [news release].

D'autres rapports CampDesrEcrues

Discuter de cet article

SUIVRE NOTRE JOURNAL